iCAD Stock Forecast, Price & News

iCAD (NASDAQ:ICAD) Frequently Asked Questions

Is iCAD a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iCAD in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" iCAD stock.
View analyst ratings for iCAD or view top-rated stocks.

How has iCAD's stock price been impacted by COVID-19 (Coronavirus)?

iCAD's stock was trading at $11.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ICAD stock has decreased by 45.2% and is now trading at $6.09.
View which stocks have been most impacted by COVID-19.

When is iCAD's next earnings date?

iCAD is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for iCAD.

How were iCAD's earnings last quarter?

iCAD, Inc. (NASDAQ:ICAD) issued its quarterly earnings results on Tuesday, November, 9th. The technology company reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.01. The technology company earned $9.36 million during the quarter, compared to the consensus estimate of $9.41 million. iCAD had a negative net margin of 23.98% and a negative trailing twelve-month return on equity of 17.38%. During the same quarter in the previous year, the business posted ($0.08) EPS.
View iCAD's earnings history.

What price target have analysts set for ICAD?

8 Wall Street analysts have issued 1 year target prices for iCAD's shares. Their forecasts range from $13.00 to $24.00. On average, they expect iCAD's stock price to reach $20.38 in the next twelve months. This suggests a possible upside of 234.6% from the stock's current price.
View analysts' price targets for iCAD or view top-rated stocks among Wall Street analysts.

Who are iCAD's key executives?

iCAD's management team includes the following people:

• Michael S. Klein, Executive Chairman & Chief Executive Officer
• Stacey M. Stevens, President (LinkedIn Profile)
• Charles R. Carter, Chief Financial Officer & Secretary
• Jonathan Go, Chief Technology Officer (LinkedIn Profile)

What is Michael Klein's approval rating as iCAD's CEO?

4 employees have rated iCAD CEO Michael Klein on Glassdoor.com. Michael Klein has an approval rating of 75% among iCAD's employees.

Who are some of iCAD's key competitors?

Some companies that are related to iCAD include Antares Pharma (ATRS), TransEnterix (TRXC), MiMedx Group (MDXG), Invo Bioscience (IVOB), UFP Technologies (UFPT), Nyxoah (NYXH), IRadimed (IRMD), Anika Therapeutics (ANIK), SeaSpine (SPNE), Vapotherm (VAPO), Apyx Medical (APYX), Accuray (ARAY), Pulse Biosciences (PLSE), Tactile Systems Technology (TCMD) and Utah Medical Products (UTMD).
View all of ICAD's competitors.

What other stocks do shareholders of iCAD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iCAD investors own include Inseego (INSG), Marvell Technology (MRVL), NVIDIA (NVDA), Aptiv (APTV), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Ambarella (AMBA), BioXcel Therapeutics (BTAI) and Telefonaktiebolaget LM Ericsson (publ) (ERIC).

What is iCAD's stock symbol?

iCAD trades on the NASDAQ under the ticker symbol "ICAD."

Who are iCAD's major shareholders?

iCAD's stock is owned by many different retail and institutional investors. Top institutional shareholders include Mesirow Financial Investment Management Inc. (0.09%). Company insiders that own iCAD stock include Andy Sassine, Charles Ross Carter, Jonathan Go, Michael S Klein, R Scott Areglado, Stacey M Stevens and Susan Alyson Wood.
View institutional ownership trends for iCAD.

Which major investors are selling iCAD stock?

ICAD stock was sold by a variety of institutional investors in the last quarter, including Mesirow Financial Investment Management Inc.. Company insiders that have sold iCAD company stock in the last year include Andy Sassine, Jonathan Go, and Stacey M Stevens.
View insider buying and selling activity for iCAD or view top insider-selling stocks.

How do I buy shares of iCAD?

Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iCAD's stock price today?

One share of ICAD stock can currently be purchased for approximately $6.09.

How much money does iCAD make?

iCAD has a market capitalization of $152.91 million and generates $29.70 million in revenue each year. The technology company earns $-17.61 million in net income (profit) each year or ($0.36) on an earnings per share basis.

How many employees does iCAD have?

iCAD employs 114 workers across the globe.

What is iCAD's official website?

The official website for iCAD is www.icadmed.com.

Where are iCAD's headquarters?

iCAD is headquartered at 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062.

How can I contact iCAD?

iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company can be reached via phone at (603) 882-5200, via email at [email protected], or via fax at 603-880-3843.